TCGA-CN-5369-01A-01R-1436-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.000228
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.630
- INTERFERON_GAMMA_RESPONSE+0.630
- IL6_JAK_STAT3_SIGNALING+0.570
- ALLOGRAFT_REJECTION+0.560
- INFLAMMATORY_RESPONSE+0.510
- COMPLEMENT+0.450
- COAGULATION+0.390
- KRAS_SIGNALING_UP+0.350
- APICAL_JUNCTION+0.300
- TNFA_SIGNALING_VIA_NFKB+0.270
Top 10 suppressed
- DNA_REPAIR-0.390
- E2F_TARGETS-0.390
- MYC_TARGETS_V2-0.390
- OXIDATIVE_PHOSPHORYLATION-0.330
- MYOGENESIS-0.300
- MYC_TARGETS_V1-0.260
- G2M_CHECKPOINT-0.200
- GLYCOLYSIS-0.150
- FATTY_ACID_METABOLISM-0.120
- ADIPOGENESIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 311f1988-e21e-4130-b944-2a34d7d46d28 | — | — | 0.886 |
| 2 | bd09bf00-3fb3-41fc-ae4d-4ac68a925a6b | — | — | 0.877 |
| 3 | C3N-02242 | — | cohortA1 | 0.876 |
| 4 | R323 | — | — | 0.864 |
| 5 | 74cffe84-dca8-4673-925a-9e0d6344832a | — | — | 0.857 |
| 6 | BS_02NZT8CE | low-grade glioma | — | 0.855 |
| 7 | c55bb20b-c929-42e2-be7f-8b1da7bee953 | — | — | 0.854 |
| 8 | TCGA-44-7672-01A-11R-2066-07 | — | cohortA1 | 0.854 |
| 9 | TCGA-MT-A67F-01A-11R-A30B-07 | — | — | 0.854 |
| 10 | 2d12ea90-c4f4-4aca-b353-360057b446e2 | — | — | 0.854 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.630 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.630 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.570 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.560 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.510 | Idelalisib | — uncovered |
| COMPLEMENT | 0.450 | Inavolisib | — uncovered |
| COAGULATION | 0.390 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.350 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.270 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.250 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.240 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.230 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.230 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.220 | Inavolisib | — uncovered |
| APOPTOSIS | 0.210 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.180 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.130 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.080 | Remibrutinib | — uncovered |